Search Results
Sep 03, 2026, 08:00 ET If you are a Black kidney disease patient registered on the national kidney transplant waitlist at a California transplant hospital or the Cedars-Sinai Medical Center, from 2000 to the present, you may be part of a lawsuit
/PRNewswire/ -- Randall v. United Network for Organ Sharing, et al., Case No. 2:23-cv-02576-MEMF-MAA, U.S. District Court for the Central District of California What is the lawsuit about?
More news about: U.S. District Court for the Central District of California
Sep 03, 2026, 08:00 ET Si usted es un paciente negro con enfermedad renal registrado en la lista de espera nacional para trasplantes de riñón en un hospital de trasplantes de California o en el Cedars-Sinai Medical Center, desde el año 2000 hasta el presente, podría formar parte de una demanda.
2026 /PRNewswire-HISPANIC PR WIRE/ -- Randall v. United Network for Organ Sharing, et al., caso n.º 2:23-cv-02576-MEMF-MAA, Tribunal de Distrito de los EE. UU. para el Distrito Central de California¿De qué trata la demanda?Las personas
More news about: Tribunal de Distrito de los Estados Unidos para el Distrito Central de California
Aug 30, 2026, 06:15 ET Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
Administration (FDA) New Drug Application (NDA) submission expected by the end of 2028 and European Medicines Agency (EMA) Marketing Authorisation Application (MAA) submission expected in early 2029.- ASC30 has the potential to become the second oral small molecule GLP-1
More news about: Ascletis Pharma Inc.
Aug 28, 2026, 07:31 ET Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma
areas of focus.In women's health, the core product CEVIRA® has made positive progress in international market development, with its MAA successfully accepted for review by the EMA. The company is actively establishing commercial partnerships in Europe, emerging markets, and Belt and Road
More news about: Asieris
Aug 28, 2026, 07:30 ET Mid-America Apartment Communities to Redeem All Outstanding Shares of Its 8.50% Series I Cumulative Redeemable Preferred Stock
Tenn., Aug. 28, 2026 /PRNewswire/ -- /PR Newswire/ -- Mid-America Apartment Communities, Inc., or MAA (NYSE: MAA), announced today that it will redeem for cash all of the outstanding shares of MAA's 8.50% Series I Cumulative Redeemable Preferred Stock, or the
More news about: MAA
Aug 13, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion regarding the Marketing Authorization Application (MAA) for arimoclomol for the treatment of Niemann-Pick disease type C (NPC), a rare, progressive and life-threatening neurodegenerative disorder." On
More news about: Pomerantz LLP
Aug 13, 2026, 08:00 ET Oracle and AWS Deepen Strategic Collaboration as Enterprise Adoption of Oracle AI Database@AWS Accelerates
CloudWatch; and building event-driven applications with Amazon EventBridge.Support for Platinum Oracle Maximum Availability Architecture (MAA): Helps customers improve resiliency, accelerate application performance, and reduce manual intervention for mission-critical Oracle AI Database@AWS
More news about: Oracle
Aug 06, 2026, 23:02 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion regarding the Marketing Authorization Application (MAA) for arimoclomol for the treatment of Niemann-Pick disease type C (NPC), a rare, progressive and life-threatening neurodegenerative disorder." On
More news about: Pomerantz LLP
Aug 06, 2026, 16:05 ET Cryoport Reports Second Quarter 2026 Financial Results
779In Q2 2026, four of our customers filed Biologics License Applications (BLA) / Marketing Authorization Applications (MAA). During the Q2 2026, Cryoport's customer, Orca Bio, received U.S. Food and Drug Administration (FDA) approval for TREGZI™ as the first and only precision-engineered
More news about: Cryoport, Inc.
Aug 06, 2026, 12:04 ET Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It
More news about: Northwest Biotherapeutics, Inc.
Aug 06, 2026, 11:58 ET Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It
More news about: Northwest Biotherapeutics, Inc.
Aug 06, 2026, 07:30 ET Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
2026, Nuvation Bio announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) validated the Marketing Authorisation Application (MAA) submitted by partner Eisai Co., Ltd. for taletrectinib for the treatment of advanced ROS1-positive non-small cell lung cancer (ROS1+ NSCLC).In
More news about: Nuvation Bio, Inc.
Aug 06, 2026, 07:00 ET National Math Talent Fund Launches to Close America's Math Graduation Gap for 10,000 College Students
the Mathematical Association of America (MAA)The Mathematical Association of America is one of the world's largest communities of mathematicians, students, and enthusiasts. With over 100 years of leadership in mathematics education, the MAA advances the understanding of mathematics and
More news about: Last Mile Education Fund
Aug 04, 2026, 16:01 ET Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
NCT06538480).MAA under review by the EMA: The European Medicines Agency (EMA) has validated and is reviewing the Marketing Authorization Application (MAA) submitted in November 2025 for zopapogene imadenovec for the treatment of adults
More news about: Precigen, Inc.
Aug 03, 2026, 06:55 ET Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
into 2029, beyond the expected submission of a New Drug Application (NDA) in the U.S. by the end of 2028 and a Marketing Authorisation Application (MAA) in Europe in early 2029 for ASC30.HONG KONG, Aug. 3, 2026 /PRNewswire/
More news about: Ascletis Pharma Inc.
Aug 03, 2026, 02:01 ET IMPACT Therapeutics firma un acuerdo de licencia exclusiva con Pharmanovia
senaparib a 66 países.La Agencia Europea de Medicamentos ("la EMA") aceptó formalmente la solicitud de autorización de comercialización (MAA) de senaparib para terapia de mantenimiento de 1 litro para pacientes adultas con cáncer de ovario avanzado en Europa en agosto de 2025, y se espera
More news about: IMPACT Therapeutics
Aug 03, 2026, 01:58 ET IMPACT Therapeutics unterzeichnet Exklusivlizenzvertrag mit Pharmanovia für Senaparib in Europa, dem Nahen Osten und Nordafrika, Australien und Neuseeland
Produkts;Die exklusive Partnerschaft erweitert die globale Reichweite von Senaparib auf 66 Länder; undDer Antrag auf Marktzulassung (MAA) von Senaparib für die Erstlinien-Erhaltungstherapie bei erwachsenen Patientinnen mit fortgeschrittenem Eierstockkrebs in Europa wurde im August 2025
More news about: IMPACT Therapeutics
Jul 31, 2026, 04:03 ET IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
product net sales;The Exclusive Partnership expands senaparib's global reach to 66 countries; andMarketing Authorisation Application (MAA) of senaparib for 1L maintenance therapy for adult patients with advanced ovarian cancer in Europe was formally accepted by the European Medicines Agency
More news about: IMPACT Therapeutics
Jul 31, 2026, 03:48 ET IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
product net sales;The Exclusive Partnership expands senaparib's global reach to 66 countries; andMarketing Authorisation Application (MAA) of senaparib for 1L maintenance therapy for adult patients with advanced ovarian cancer in Europe was formally accepted by the European Medicines Agency
More news about: IMPACT Therapeutics
Jul 30, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)." Specifically, the press release
More news about: Pomerantz LLP
Jul 30, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion regarding the Marketing Authorization Application (MAA) for arimoclomol for the treatment of Niemann-Pick disease type C (NPC), a rare, progressive and life-threatening neurodegenerative disorder."On
More news about: Pomerantz LLP
Jul 30, 2026, 08:10 ET Parks Associates: 60% of Communities With Bulk Internet Service Also Provide Property-Wide Wi-Fi
CalixMariam Rogers Walker, Sr. Director, Community Sales, Chamberlain GroupDavid Rubin, VP, AEI ConsultantsJosh Siddon, VP, IT Architecture, MAA – Mid-America Apartment CommunitiesTodd Thorpe, Director of Business Development, Cambium NetworksAntonio Torres, Zentra Business Development
More news about: Parks Associates
Jul 29, 2026, 16:15 ET MAA REPORTS SECOND QUARTER 2026 RESULTS
buying single-family homes of 10.9% for the quarter.During the second quarter of 2026, MAA completed the initial lease-up of MAA Cathedral Arts in Dallas, Texas, completed the development of MAA Plaza Midwood located in Charlotte, North Carolina and began construction of a multifamily apartment
More news about: MAA
Jul 27, 2026, 07:52 ET Setting a new benchmark in premium lifestyle living, Venus Group introduces 'The Universe' in Ahmedabad
that buying a home should be as straightforward as living in one.RERA number: PR/GJ/AHMEDABAD/AHMEDABAD CITY/Ahmedabad Municipal Corporation/MAA17082/080726/311232Homebuyers can experience the project firsthand at the Sales Experience Centre in Nehru Nagar or discover more by visiting
More news about: Venus Group
Jul 23, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)." Specifically, the press release
More news about: Pomerantz LLP